{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T11:45:06Z","timestamp":1795088706156,"version":"4.10.2"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Topiramate is a repurposed first-line treatment for migraine prophylaxis. The aim of this systematic review and meta-analysis is to critically re-appraise the existing evidence supporting the efficacy and tolerability of topiramate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic search in MEDLINE, EMBASE, Cochrane CENTRAL, and ClinicalTrials.gov was performed for trials of pharmacological treatment in migraine prophylaxis as of August 13, 2022, following the Preferred Reporting Items for Systematic Reviews (PRISMA). Randomized controlled trials in adult patients that used topiramate for the prophylactic treatment of migraine, with placebo as active comparator, were included. Two reviewers independently screened the retrieved studies and extracted all data. Outcomes of interest were the 50% responder rates, the reduction in monthly migraine days, and adverse events leading to treatment discontinuation. Results were pooled and meta-analyzed, with sensitivity analysis based on the risk of bias of the studies, the monthly migraine days at baseline, and the previous use of other prophylactic treatments. Certainty evidence was judged according to the GRADE framework.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eight out of 10,826 studies fulfilled the inclusion\/exclusion criteria, accounting for 2,610 randomized patients. Six studies included patients with episodic migraine and two with chronic migraine. Topiramate dose ranged from 50 to 200\u00a0mg\/day, and all studies included a placebo arm. There was a high certainty that topiramate: 1) increased the proportion of patients who achieved a 50% responder rate in monthly migraine days, compared to placebo [relative risk: 1.61 (95% confidence interval (CI): 1.29\u20132.01); absolute risk difference: 168 more per 1,000 (95% CI: 80 to 278 more)]; 2) was associated with 0.99 (95% CI: 1.41\u20130.58) fewer migraine days than placebo; 3) and had a higher proportion of patients with adverse events leading to treatment discontinuation [absolute risk difference 80 patients more per 1,000 (95% CI: 20 to 140 more patients)].<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>There is high-quality evidence of the efficacy of topiramate in the prophylaxis of migraine, albeit its use poses a risk of adverse events that may lead to treatment discontinuation, with a negative effect on patient satisfaction and adherence to care.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-023-01671-5","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T23:02:55Z","timestamp":1696892575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["European Headache Federation (EHF) critical reappraisal and meta-analysis of oral drugs in migraine prevention \u2013 part 3: topiramate"],"prefix":"10.1186","volume":"24","author":[{"given":"Bianca","family":"Raffaelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Garc\u00eda-Azor\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre M.","family":"Boucherie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal Mohammad","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina I.","family":"Deligianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Gil-Gouveia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kirsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lampl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Uluduz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Versijpt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"MaassenVanDenBrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena","family":"Zeraatkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Sanchez-del-Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"key":"1671_CR1","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1021\/jm00388a023","volume":"30","author":"BE Maryanoff","year":"1987","unstructured":"Maryanoff BE, Nortey SO, Gardocki JF et al (1987) Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate and related compounds. J Med Chem 30:880\u2013887. https:\/\/doi.org\/10.1021\/jm00388a023","journal-title":"J Med Chem"},{"key":"1671_CR2","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1046\/j.1468-2982.2002.00380.x","volume":"22","author":"WB Young","year":"2002","unstructured":"Young WB, Hopkins MM, Shechter AL et al (2002) Topiramate: a case series study in migraine prophylaxis. Cephalalgia 22:659\u2013663. https:\/\/doi.org\/10.1046\/j.1468-2982.2002.00380.x","journal-title":"Cephalalgia"},{"key":"1671_CR3","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1046\/j.1526-4610.2002.02184.x","volume":"42","author":"RL Von Seggern","year":"2002","unstructured":"Von Seggern RL, Mannix LK, Adelman JU (2002) Efficacy of topiramate in migraine prophylaxis: a retrospective chart analysis. Headache 42:804\u2013809. https:\/\/doi.org\/10.1046\/j.1526-4610.2002.02184.x","journal-title":"Headache"},{"key":"1671_CR4","first-page":"364","volume":"18","author":"J Pascual","year":"2003","unstructured":"Pascual J, del S\u00e1nchez Rio M, Mateos V et al (2003) Topiramate for patients with refractory migraine: an observational, multicenter study in Spain. Neurologia 18:364\u2013367","journal-title":"Neurologia"},{"key":"1671_CR5","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1046\/j.1526-4610.2001.01190.x","volume":"41","author":"JR Storey","year":"2001","unstructured":"Storey JR, Calder CS, Hart DE et al (2001) Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 41:968\u2013975. https:\/\/doi.org\/10.1046\/j.1526-4610.2001.01190.x","journal-title":"Headache"},{"key":"1671_CR6","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1001\/jama.291.8.965","volume":"291","author":"JL Brandes","year":"2004","unstructured":"Brandes JL, Saper JR, Diamond M et al (2004) Topiramate for migraine prevention: a randomized controlled trial. Jama 291:965\u2013973. https:\/\/doi.org\/10.1001\/jama.291.8.965","journal-title":"Jama"},{"key":"1671_CR7","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/wnl.55.6.754","volume":"55","author":"SD Silberstein","year":"2000","unstructured":"Silberstein SD (2000) Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55:754\u2013762. https:\/\/doi.org\/10.1212\/wnl.55.6.754","journal-title":"Neurology"},{"key":"1671_CR8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.tips.2007.02.005","volume":"28","author":"P Calabresi","year":"2007","unstructured":"Calabresi P, Galletti F, Rossi C et al (2007) Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. Trends Pharmacol Sci 28:188\u2013195. https:\/\/doi.org\/10.1016\/j.tips.2007.02.005","journal-title":"Trends Pharmacol Sci"},{"key":"1671_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1177\/1073858405275554","volume":"11","author":"D Pietrobon","year":"2005","unstructured":"Pietrobon D (2005) Migraine: new molecular mechanisms. Neuroscientist 11:373\u2013386. https:\/\/doi.org\/10.1177\/1073858405275554","journal-title":"Neuroscientist"},{"key":"1671_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrn1430","volume":"5","author":"MA Rogawski","year":"2004","unstructured":"Rogawski MA, L\u00f6scher W (2004) The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5:553\u2013564. https:\/\/doi.org\/10.1038\/nrn1430","journal-title":"Nat Rev Neurosci"},{"key":"1671_CR11","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1111\/bph.15657","volume":"178","author":"F Zobdeh","year":"2021","unstructured":"Zobdeh F, Ben Kraiem A, Attwood MM et al (2021) Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments. Br J Pharmacol 178:4588\u20134607. https:\/\/doi.org\/10.1111\/bph.15657","journal-title":"Br J Pharmacol"},{"key":"1671_CR12","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/j.1468-2982.2004.00767.x","volume":"24","author":"RJ Storer","year":"2004","unstructured":"Storer RJ, Goadsby PJ (2004) Topiramate inhibits trigeminovascular neurons in the cat. Cephalalgia 24:1049\u20131056. https:\/\/doi.org\/10.1111\/j.1468-2982.2004.00767.x","journal-title":"Cephalalgia"},{"key":"1671_CR13","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2147\/nedt.2006.2.4.475","volume":"2","author":"M Mula","year":"2006","unstructured":"Mula M, Cavanna AE, Monaco F (2006) Psychopharmacology of topiramate: from epilepsy to bipolar disorder. Neuropsychiatr Dis Treat 2:475\u2013488. https:\/\/doi.org\/10.2147\/nedt.2006.2.4.475","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1671_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1468-2982.2009.02021.x","volume":"30","author":"PR Holland","year":"2010","unstructured":"Holland PR, Akerman S, Goadsby PJ (2010) Cortical spreading depression-associated cerebral blood flow changes induced by mechanical stimulation are modulated by AMPA and GABA receptors. Cephalalgia 30:519\u2013527. https:\/\/doi.org\/10.1111\/j.1468-2982.2009.02021.x","journal-title":"Cephalalgia"},{"key":"1671_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/head.12997","volume":"57","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD (2017) Topiramate in migraine prevention: a 2016 perspective. Headache 57:165\u2013178. https:\/\/doi.org\/10.1111\/head.12997","journal-title":"Headache"},{"key":"1671_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1586\/17512433.2014.885835","volume":"7","author":"J Hoffmann","year":"2014","unstructured":"Hoffmann J, Akerman S, Goadsby PJ (2014) Efficacy and mechanism of anticonvulsant drugs in migraine. Expert Rev Clin Pharmacol 7:191\u2013201. https:\/\/doi.org\/10.1586\/17512433.2014.885835","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1671_CR17","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ana.20778","volume":"59","author":"C Ayata","year":"2006","unstructured":"Ayata C, Jin H, Kudo C et al (2006) Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 59:652\u2013661. https:\/\/doi.org\/10.1002\/ana.20778","journal-title":"Ann Neurol"},{"key":"1671_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s10194-023-01573-6","volume":"24","author":"C Lampl","year":"2023","unstructured":"Lampl C, Versijpt J, Amin FM et al (2023) European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 1: amitriptyline. J Headache Pain 24:39. https:\/\/doi.org\/10.1186\/s10194-023-01573-6","journal-title":"J Headache Pain"},{"key":"1671_CR19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s10194-023-01657-3","volume":"24","author":"CI Deligianni","year":"2023","unstructured":"Deligianni CI, Sacco S, Ekizoglu E et al (2023) European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 2: flunarizine. J Headache Pain 24:128. https:\/\/doi.org\/10.1186\/s10194-023-01657-3","journal-title":"J Headache Pain"},{"key":"1671_CR20","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"Bmj"},{"key":"1671_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/0333102414534325","volume":"35","author":"WM Mulleners","year":"2015","unstructured":"Mulleners WM, McCrory DC, Linde M (2015) Antiepileptics in migraine prophylaxis: an updated Cochrane review. Cephalalgia 35:51\u201362. https:\/\/doi.org\/10.1177\/0333102414534325","journal-title":"Cephalalgia"},{"key":"1671_CR22","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","volume":"38","author":"C Tassorelli","year":"2018","unstructured":"Tassorelli C, Diener HC, Dodick DW et al (2018) Guidelines of the international headache society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 38:815\u2013832. https:\/\/doi.org\/10.1177\/0333102418758283","journal-title":"Cephalalgia"},{"key":"1671_CR23","doi-asserted-by":"publisher","first-page":"e043242","DOI":"10.1136\/bmjopen-2020-043242","volume":"11","author":"K Haywood","year":"2021","unstructured":"Haywood K, Potter R, Froud R et al (2021) Core outcome set for preventive intervention trials in chronic and episodic migraine (COSMIG): an international, consensus-derived and multistakeholder initiative. BMJ Open 11:e043242. https:\/\/doi.org\/10.1136\/bmjopen-2020-043242","journal-title":"BMJ Open"},{"key":"1671_CR24","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/jrsm.1259","volume":"8","author":"G R\u00fccker","year":"2017","unstructured":"R\u00fccker G, Cates CJ, Schwarzer G (2017) Methods for including information from multi-arm trials in pairwise meta-analysis. Res Synth Methods 8:392\u2013403. https:\/\/doi.org\/10.1002\/jrsm.1259","journal-title":"Res Synth Methods"},{"key":"1671_CR25","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1136\/thoraxjnl-2021-217976","volume":"77","author":"T Pitre","year":"2022","unstructured":"Pitre T, Mah J, Helmeczi W et al (2022) Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis. Thorax 77:1243\u20131250. https:\/\/doi.org\/10.1136\/thoraxjnl-2021-217976","journal-title":"Thorax"},{"key":"1671_CR26","doi-asserted-by":"publisher","first-page":"m2980","DOI":"10.1136\/bmj.m2980","volume":"370","author":"RA Siemieniuk","year":"2020","unstructured":"Siemieniuk RA, Bartoszko JJ, Zeraatkar D et al (2020) Drug treatments for covid-19: living systematic review and network meta-analysis. Bmj 370:m2980. https:\/\/doi.org\/10.1136\/bmj.m2980","journal-title":"Bmj"},{"key":"1671_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 22:153\u2013160. https:\/\/doi.org\/10.1136\/ebmental-2019-300117","journal-title":"Evid Based Ment Health"},{"key":"1671_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw 36:1\u201348. https:\/\/doi.org\/10.18637\/jss.v036.i03","journal-title":"J Stat Softw"},{"key":"1671_CR29","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Bmj 336:924\u2013926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","journal-title":"Bmj"},{"key":"1671_CR30","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/archneur.61.4.490","volume":"61","author":"SD Silberstein","year":"2004","unstructured":"Silberstein SD, Neto W, Schmitt J et al (2004) Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 61:490\u2013495. https:\/\/doi.org\/10.1001\/archneur.61.4.490","journal-title":"Arch Neurol"},{"key":"1671_CR31","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00415-004-0464-6","volume":"251","author":"HC Diener","year":"2004","unstructured":"Diener HC, Tfelt-Hansen P, Dahl\u00f6f C et al (2004) Topiramate in migraine prophylaxis\u2013results from a placebo-controlled trial with propranolol as an active control. J Neurol 251:943\u2013950. https:\/\/doi.org\/10.1007\/s00415-004-0464-6","journal-title":"J Neurol"},{"key":"1671_CR32","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10072-004-0350-0","volume":"25","author":"D Mei","year":"2004","unstructured":"Mei D, Capuano A, Vollono C et al (2004) Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. Neurol Sci 25:245\u2013250. https:\/\/doi.org\/10.1007\/s10072-004-0350-0","journal-title":"Neurol Sci"},{"key":"1671_CR33","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.clinthera.2006.07.003","volume":"28","author":"SD Silberstein","year":"2006","unstructured":"Silberstein SD, Hulihan J, Karim MR et al (2006) Efficacy and tolerability of topiramate 200 mg\/d in the prevention of migraine with\/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. Clin Ther 28:1002\u20131011. https:\/\/doi.org\/10.1016\/j.clinthera.2006.07.003","journal-title":"Clin Ther"},{"key":"1671_CR34","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","volume":"27","author":"HC Diener","year":"2007","unstructured":"Diener HC, Bussone G, Van Oene JC et al (2007) Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27:814\u2013823. https:\/\/doi.org\/10.1111\/j.1468-2982.2007.01326.x","journal-title":"Cephalalgia"},{"key":"1671_CR35","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1526-4610.2006.00684.x","volume":"47","author":"SD Silberstein","year":"2007","unstructured":"Silberstein SD, Lipton RB, Dodick DW et al (2007) Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 47:170\u2013180. https:\/\/doi.org\/10.1111\/j.1526-4610.2006.00684.x","journal-title":"Headache"},{"key":"1671_CR36","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1526-4610.2009.01508.x","volume":"49","author":"S Silberstein","year":"2009","unstructured":"Silberstein S, Lipton R, Dodick D et al (2009) Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 49:1153\u20131162. https:\/\/doi.org\/10.1111\/j.1526-4610.2009.01508.x","journal-title":"Headache"},{"key":"1671_CR37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/0333102410372427","volume":"31","author":"RB Lipton","year":"2011","unstructured":"Lipton RB, Silberstein S, Dodick D et al (2011) Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia 31:18\u201330. https:\/\/doi.org\/10.1177\/0333102410372427","journal-title":"Cephalalgia"},{"key":"1671_CR38","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-023-01594-1","volume":"24","author":"C Lampl","year":"2023","unstructured":"Lampl C, MaassenVanDenBrink A, Deligianni CI et al (2023) The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain 24:56. https:\/\/doi.org\/10.1186\/s10194-023-01594-1","journal-title":"J Headache Pain"},{"key":"1671_CR39","doi-asserted-by":"publisher","first-page":"Cd010610","DOI":"10.1002\/14651858.Cd010610","volume":"2013","author":"M Linde","year":"2013","unstructured":"Linde M, Mulleners WM, Chronicle EP et al (2013) Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013:Cd010610. https:\/\/doi.org\/10.1002\/14651858.Cd010610","journal-title":"Cochrane Database Syst Rev"},{"key":"1671_CR40","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12916-017-0845-1","volume":"15","author":"AA Veroniki","year":"2017","unstructured":"Veroniki AA, Cogo E, Rios P et al (2017) Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med 15:95. https:\/\/doi.org\/10.1186\/s12916-017-0845-1","journal-title":"BMC Med"},{"key":"1671_CR41","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/jamaneurol.2022.1269","volume":"79","author":"MH Bj\u00f8rk","year":"2022","unstructured":"Bj\u00f8rk MH, Zoega H, Leinonen MK et al (2022) Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability. JAMA Neurol 79:672\u2013681. https:\/\/doi.org\/10.1001\/jamaneurol.2022.1269","journal-title":"JAMA Neurol"},{"key":"1671_CR42","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/aog.0000000000004697","volume":"139","author":"A Lazorwitz","year":"2022","unstructured":"Lazorwitz A, Pena M, Sheeder J et al (2022) Effect of topiramate on serum etonogestrel concentrations among contraceptive implant users. Obstet Gynecol 139:579\u2013587. https:\/\/doi.org\/10.1097\/aog.0000000000004697","journal-title":"Obstet Gynecol"},{"key":"1671_CR43","unstructured":"European Medicines Agency. PRAC recommendation. Topiramate. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/topiramate. Accessed on Monday 11th, 2023."},{"key":"1671_CR44","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1111\/head.13653","volume":"59","author":"JF Rothrock","year":"2019","unstructured":"Rothrock JF, Adams AM, Lipton RB et al (2019) FORWARD study: evaluating the comparative effectiveness of OnabotulinumtoxinA and Topiramate for headache prevention in adults with chronic migraine. Headache 59:1700\u20131713. https:\/\/doi.org\/10.1111\/head.13653","journal-title":"Headache"},{"key":"1671_CR45","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/03331024211053571","volume":"42","author":"U Reuter","year":"2022","unstructured":"Reuter U, Ehrlich M, Gendolla A et al (2022) Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia 42:108\u2013118. https:\/\/doi.org\/10.1177\/03331024211053571","journal-title":"Cephalalgia"},{"key":"1671_CR46","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1177\/03331024211047454","volume":"42","author":"D Chowdhury","year":"2022","unstructured":"Chowdhury D, Bansal L, Duggal A et al (2022) TOP-PRO study: A randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine. Cephalalgia 42:396\u2013408. https:\/\/doi.org\/10.1177\/03331024211047454","journal-title":"Cephalalgia"},{"key":"1671_CR47","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.clinthera.2009.03.020","volume":"31","author":"DW Dodick","year":"2009","unstructured":"Dodick DW, Freitag F, Banks J, CAPSS-277 Investigator Group et al (2009) Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 31:542\u201359. https:\/\/doi.org\/10.1016\/j.clinthera.2009.03.020","journal-title":"Clin Ther"},{"key":"1671_CR48","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.clineuro.2008.05.025","volume":"110","author":"K Keskinbora","year":"2008","unstructured":"Keskinbora K, Aydinli I (2008) A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg 110:979\u2013984. https:\/\/doi.org\/10.1016\/j.clineuro.2008.05.025","journal-title":"Clin Neurol Neurosurg"},{"key":"1671_CR49","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/ane.12626","volume":"135","author":"KL Lai","year":"2017","unstructured":"Lai KL, Niddam DM, Fuh JL et al (2017) Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial. Acta Neurol Scand 135:476\u2013483. https:\/\/doi.org\/10.1111\/ane.12626","journal-title":"Acta Neurol Scand"},{"key":"1671_CR50","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/j.1526-4637.2011.01295.x","volume":"13","author":"N Luo","year":"2012","unstructured":"Luo N, Di W, Zhang A et al (2012) A randomized, one-year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis. Pain Med 13:80\u201386. https:\/\/doi.org\/10.1111\/j.1526-4637.2011.01295.x","journal-title":"Pain Med"},{"key":"1671_CR51","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/WNF.0b013e318225140c","volume":"34","author":"SE Mohammadianinejad","year":"2011","unstructured":"Mohammadianinejad SE, Abbasi V, Sajedi SA, Majdinasab N, Abdollahi F, Hajmanouchehri R, Faraji A (2011) Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial. Clin Neuropharmacol 34:174\u2013177. https:\/\/doi.org\/10.1097\/WNF.0b013e318225140c","journal-title":"Clin Neuropharmacol"},{"key":"1671_CR52","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40263-021-00834-9","volume":"35","author":"LH Overeem","year":"2021","unstructured":"Overeem LH, Raffaelli B, Mecklenburg J et al (2021) Indirect comparison of Topiramate and Monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta-analysis. CNS Drugs 35:805\u2013820. https:\/\/doi.org\/10.1007\/s40263-021-00834-9","journal-title":"CNS Drugs"},{"key":"1671_CR53","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1177\/03331024211018137","volume":"41","author":"F Frank","year":"2021","unstructured":"Frank F, Ulmer H, Sidoroff V et al (2021) CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis. Cephalalgia 41:1222\u20131239. https:\/\/doi.org\/10.1177\/03331024211018137","journal-title":"Cephalalgia"},{"key":"1671_CR54","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s10194-021-01228-4","volume":"22","author":"HW Schytz","year":"2021","unstructured":"Schytz HW, Amin FM, Jensen RH et al (2021) Reference programme: diagnosis and treatment of headache disorders and facial pain Danish headache society 3rd edition, 2020. J Headache Pain 22:22. https:\/\/doi.org\/10.1186\/s10194-021-01228-4","journal-title":"J Headache Pain"},{"key":"1671_CR55","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/j.1526-4610.2006.00506.x","volume":"46","author":"A Rapoport","year":"2006","unstructured":"Rapoport A, Mauskop A, Diener HC et al (2006) Long-term migraine prevention with topiramate: open-label extension of pivotal trials. Headache 46:1151\u20131160. https:\/\/doi.org\/10.1111\/j.1526-4610.2006.00506.x","journal-title":"Headache"},{"key":"1671_CR56","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/s1474-4422(07)70272-7","volume":"6","author":"HC Diener","year":"2007","unstructured":"Diener HC, Agosti R, Allais G et al (2007) Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 6:1054\u20131062. https:\/\/doi.org\/10.1016\/s1474-4422(07)70272-7","journal-title":"Lancet Neurol"},{"key":"1671_CR57","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s10194-019-0971-6","volume":"20","author":"D Garc\u00eda-Azorin","year":"2019","unstructured":"Garc\u00eda-Azorin D, Santos-Lasaosa S, Gago-Veiga AB et al (2019) Real world preventative drug management of migraine among Spanish neurologists. J Headache Pain 20:19. https:\/\/doi.org\/10.1186\/s10194-019-0971-6","journal-title":"J Headache Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01671-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01671-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01671-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T03:02:20Z","timestamp":1700535740000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01671-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1671"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01671-5","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]},"assertion":[{"value":"25 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Deirdre M. Boucherie, Sarah Kirsh and Dena Zeraatkar report no conflict of interest.Bianca Raffaelli has received honoraria for lectures\/presentations from AbbVie\/Allergan, Eli Lilly, Lundbeck, Novartis, and Teva. Bianca Raffaelli has received research funding from Novartis, the German Research Foundation and the German Migraine and Headache Society. Bianca Raffaelli serves of Junior Editor for The Journal of Headache and Pain and as associate editor for Frontiers in Neurology.David Garc\u00eda-Azor\u00edn has received personal compensation for consulting\/advising from the World Health Organization. Non-profit board membership in the Spanish Society of Neurology, and the European Union of Medical Specialist section of Neurology. Research funding from the Regional Health Administration (Gerencia Regional de Salud SACYL) in Castilla y Leon, Spain. Speaker\/travel grants\/clinical trials from Teva, Allergan, Amgen, Eli Lilly, Lundbeck, Novartis, and Biohaven.Faisal Mohammad Amin has received honoraria for delivering lectures and\/or participation in advisory boards for AbbVie, Pfizer, Teva, Lundbeck, Novartis and Eli Lilly. Faisal Mohammad Amin serves as associate editor for the journals Headache Medicine, Acta Neurologica Scandinavica, Frontiers in Neurology and Frontiers In Pain Research. Faisal Mohammad Amin serves as president of the Danish Headache Society and a member of the Board of Directors in European Headache Federation.Christina I Deligianni has received IHS research fellowship grant, scholarship from Hellenic society of Neurology. Christina I Deligianni serves as a member of the Board of Directors in the European Headache Federation.Raquel Gil-Gouveia reports honoraria for lectures\/presentations from AbbVie\/Allergan, Eli Lily, Lundbeck, Novartis, Teva, Organon, Pfizer; participated in clinical trials as the principal investigator for AMGEN, Novartis, Lundbeck. research grants from Novartis. Raquel Gil-Gouveia serves as a member of the Board of Directors in European Headache Federation.Christian Lampl has received consulting fees and honoraria for lectures\/presentations from AbbVie\/Allergan, Eli Lilly, Lundbeck, Novartis, Pfizer and Teva. CL participated in clinical trials as the principal investigator for Eli Lilly. Intellectual Christian Lampl is president of the European Headache Federation and associate editor for The Journal of Headache and Pain.Simona Sacco reports personal fees as speaker or advisor for Abbott, Allergan-Abbvie, AstraZeneca, Eli Lilly, Lundbeck, Novartis, NovoNordisk, Pfizer, Teva; research grants from Novartis and Uriach; fees for CME\/education from Medscape and Neurodiem Ology Medical Education; Intellectual as president elect European Stroke Organisation, second vice president of the European Headache Federation, specialty chief editor in Headache and Neurogenic Pain for Frontiers in Neurology, associate editor for The Journal of Headache and Pain, assistant editor for Stroke.Derya Uluduz receives honoraria from Allergan-Abbvie, TEVA; consulting fees and honoraria for lectures\/presentations from Eli Lily, Novartis, Allergan\/Abbvie and Neutec participated in clinical trials as the sub-investigator for AMGEN, Novartis. Derya Uluduz serves as a member of the Board of Directors in the European Headache Federation.Jan Versijpt received personal fees and nonfinancial support from Teva, personal fees from Novartis and Lundbeck, and grants and nonfinancial support from Allergan\/Abbvie. Jan Versijpt serves as a member of the Board of Directors in the European Headache Federation.Antoinette MaassenVanDenBrink received honoraria, research and\/or travel grants from Allergan\/Abbvie, Amgen\/Novartis, Eli Lilly, Satsuma and Teva as principal investigator. Intellectual Antoinette MaassenVanDenBrink is vice-president of the European Headache Federation and associate editor for The Journal of Headache and Pain.Margarita Sanchez-del-Rio has received consulting fees and honoraria for lectures\/presentations from Eli Lily, Lundbeck, Novartis, Teva and Pfizer. Intellectual as Secretary of the European Headache Federation, Review Editor on the Editorial Board of Headache and Neurogenic Pain (specialty section of Frontiers in Neurology). Margarita Sanchez-del-Rio serves as a member of the Board of Directors in the European Headache Federation.Uwe Reuter has received consulting fees, research grants or fees for presentations from Abbie, Allegan, Amgen, Lilly, Lundbeck, Medscape, Novartis, Pfizer, StreaMedup, Teva and the German Government (BMBF). Uwe Reuter is treasurer of the European Headache Federation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"134"}}